Key Investor Signals
Secured £700,000 in pre-seed funding
A January 2026 financing led by SFC Capital and Clarendon Fund Managers supports progression from proof of concept to a minimum viable product and a preliminary laboratory study.
Established research collaboration with Strathclyde
Biomarx is working with the University of Strathclyde on electrochemical biosensing development, including a venture-capital-backed PhD programme. The university is also an investor.
Won Northern Ireland’s Seedcorn Deep Tech category
Biomarx won the regional Deep Tech category in InterTradeIreland’s 2025 investor-readiness competition, securing €50,000 and a place in the all-island final.
Team
Sean Macfarlane
Founder & CEO
- Worked in molecular diagnostics at Randox, including an extraction-scientist role handling the preparation of genetic material.
- Held a senior laboratory-scientist role at DiCroMed from 2024, adding clinical laboratory experience before founding Biomarx.
- Earned a bachelor’s degree in cellular and molecular biology at the University of Glasgow, providing a foundation in molecular disease mechanisms.
Product
Biomarx combines sample extraction, isothermal amplification and electrochemical biosensors in an automated liquid biopsy platform. The first test is being developed for non-small cell lung cancer, using circulating tumour DNA to support detection, monitoring and treatment stratification.
Automated sample preparation
The platform integrates extraction of genetic material from a blood sample into a sample-to-answer workflow. Automation is intended to reduce manual handling and the specialist skills needed to prepare samples for genomic testing.
Isothermal target amplification
Proprietary isothermal amplification increases the amount of target genetic material at a constant temperature. This approach is intended to simplify the equipment needed before the amplified material reaches the detection stage.
Electrical genetic-signal detection
Electrochemical biosensors read the amplified genetic signal electrically. Biomarx targets results in under two hours at around £70 per test, with an initial research-use-only release followed by development toward clinical diagnostic use.
Market Overview
Liquid biopsy suppliers sell test kits, instruments and laboratory services to hospitals, diagnostic laboratories and research organizations. Blood-based analysis supports cancer detection, therapy selection and repeat monitoring, creating demand for reliable molecular results with shorter turnaround times.
The early-detection and monitoring segment includes both centralized sequencing services and simpler near-patient platforms. Hospitals and laboratories evaluate clinical utility, workflow fit and reimbursement when adopting tests; repeat monitoring creates demand for consumables as well as analytical equipment.
Global liquid biopsy revenue across kits, instruments and services was estimated at $4.03B in 2025.
Global liquid biopsy revenue is forecast to grow 11.8% annually from 2025 to 2030.
Hospitals accounted for an estimated 42.5% of global liquid biopsy revenue for early cancer detection and monitoring in 2025.
Lung cancer represented an estimated 22.8% of global liquid biopsy revenue for early cancer detection and monitoring in 2025.
Comparable Outcomes
GRAIL
Developed blood-based genomic tests designed to detect multiple cancers before symptoms appeared. Illumina completed the cash-and-stock acquisition in 2021 after announcing $8B in consideration plus future revenue-linked payments.
Guardant Health
Guardant Health develops blood-based genomic tests that help clinicians characterize cancer and guide treatment, using circulating tumour DNA. The October 2018 IPO closed with 14.375 million shares sold at $19 each, including the full underwriters’ option. Gross proceeds were approximately $273.1M before fees and expenses.
Interested in More Startups Like Biomarx?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.